• Neurotech will extend its Phase 1/2 trial after ethics approval
  • Alcidion makes further inroads into UK’s public hospitals


Neurotech to extend Phase 1/2 trial after ethics approval

Paediatric neurological disorders specialist, Neurotech (ASX:NTI) has been granted an ethics approval to extend its Phase I/II clinical trial of NTI164.

The trial is studying the effects of NTI164 on children diagnosed with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS).

The trial completed recruitment of 15 paediatric patients earlier this month, with clinical results anticipated in Q3 of this year.

An extension to the trial is now needed as to allow children to continue to receive treatment when they turn 18 years of age.

The previous HREC approval (Human Research Ethics Committee) received in January only allowed those PANDAS/PANS patients who were aged 1-17 years of age to participate in the trial.

This new approval extends that to 20 years of age.


Alcidion makes further inroads in UK

Medtech company Alcidion Group (ASX:ALC) has renewed its contract with Royal Wolverhampton NHS Trust for two more years.

The contract is for the use of Alcidion’s Silverlink Patient Care System (PCS) solution, and represents the fourth contract renewal Alcidion has received from its customers.

The combined total contract value (TCV) is $3.3m over the respective renewal periods, which further bolsters Alcidion’s recurring revenue.

The third such contract renewal was recently done in Q2 with University Hospitals Dorset NHS Foundation Trust for three more years.

The successful renewal of both customers has now triggered the second tranche (£1.5m) of the earn-out consideration as part of the Silverlink acquisition.

Alcidion says it will fund this payout to Silverlink from its current cash on hand of $15.6m.

Alcidion acquired Silverlink in December 2021. Silverlink is one of the largest specialist PAS (Patient Care System) providers servicing the UK NHS (national health system) market.


Share prices today: